Navicare Biotech Co., Ltd. (8472) Stock Statistics & Valuation Metrics
Total Valuation
Navicare Biotech Co., Ltd. has a market cap or net worth of TWD 869.05M. The enterprise value is TWD 1.60B.
- Market Cap
- TWD 869.05M
- Enterprise Value
- TWD 1.60B
Share Statistics
Navicare Biotech Co., Ltd. has 17,735,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 17,735,800
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Navicare Biotech Co., Ltd.’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is -5.24%.
- Return on Equity (ROE)
- -0.09
- Return on Assets (ROA)
- -0.02
- Return on Invested Capital (ROIC)
- -5.24%
- Return on Capital Employed (ROCE)
- -0.06
- Revenue Per Employee
- 5.98M
- Profits Per Employee
- -290.90K
- Employee Count
- 80
- Asset Turnover
- 0.46
- Inventory Turnover
- 8.37
Valuation Ratios
The current PE Ratio of Navicare Biotech Co., Ltd. is -76.80. Navicare Biotech Co., Ltd.’s PEG ratio is -0.47.
- PE Ratio
- -76.80
- PS Ratio
- 1.72
- PB Ratio
- 3.35
- Price to FCF
- -34.48
- Price to Operating Cash Flow
- -35.51
- PEG Ratio
- -0.47
Income Statement
In the last 12 months, Navicare Biotech Co., Ltd. had revenue of 478.07M and earned -23.27M in profits. Earnings per share was -1.31.
- Revenue
- 478.07M
- Gross Profit
- 172.16M
- Operating Income
- -31.82M
- Pretax Income
- -20.77M
- Net Income
- -23.27M
- EBITDA
- -15.09M
- Earnings Per Share (EPS)
- -1.31
Cash Flow
In the last 12 months, operating cash flow was -24.43M and capital expenditures -850,000, giving a free cash flow of -25.28M billion.
- Operating Cash Flow
- -24.43M
- Free Cash Flow
- -25.28M
- Free Cash Flow per Share
- -1.43
Dividends & Yields
Navicare Biotech Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.85%
- Earnings Yield
- -1.29%
Stock Price Statistics
- Beta
- 0.37
- 52-Week Price Change
- -40.75%
- 50-Day Moving Average
- 69.18
- 200-Day Moving Average
- 71.92
- Relative Strength Index (RSI)
- 22.43
- Average Volume (3m)
- 21.64K
Important Dates
Navicare Biotech Co., Ltd. upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Navicare Biotech Co., Ltd. as a current ratio of 0.68, with Debt / Equity ratio of 121.06%
- Current Ratio
- 0.68
- Quick Ratio
- 0.61
- Debt to Market Cap
- 0.26
- Net Debt to EBITDA
- -11.15
- Interest Coverage Ratio
- -4.20
Taxes
In the past 12 months, Navicare Biotech Co., Ltd. has paid 2.50M in taxes.
- Income Tax
- 2.50M
- Effective Tax Rate
- -0.12
Enterprise Valuation
Navicare Biotech Co., Ltd. EV to EBITDA ratio is -256.91, with an EV/FCF ratio of -44.93.
- EV to Sales
- 2.25
- EV to EBITDA
- -256.91
- EV to Free Cash Flow
- -44.93
- EV to Operating Cash Flow
- -46.50
Balance Sheet
Navicare Biotech Co., Ltd. has TWD 165.13M in cash and marketable securities with TWD 318.39M in debt, giving a net cash position of -TWD 153.26M billion.
- Cash & Marketable Securities
- TWD 165.13M
- Total Debt
- TWD 318.39M
- Net Cash
- -TWD 153.26M
- Net Cash Per Share
- -TWD 8.64
- Tangible Book Value Per Share
- TWD 14.41
Margins
Gross margin is 35.80%, with operating margin of -3.97%, and net profit margin of -2.26%.
- Gross Margin
- 35.80%
- Operating Margin
- -3.97%
- Pretax Margin
- -0.15%
- Net Profit Margin
- -2.26%
- EBITDA Margin
- -0.87%
- EBIT Margin
- -2.74%
Analyst Forecast
The average price target for Navicare Biotech Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 30.75%
- EPS Growth Forecast
- 80.71%
